MREO
USDMereo BioPharma Group plc American Depositary Shares
Reaalajas hind
Hinnagraafik
Põhinäitajad
Turunäitajad
Avatud
$1.830
Kõrge
$1.880
Madal
$1.780
Maht
1.12M
Ettevõtte fundamentaalnäitajad
Turukapitalisatsioon
283.2M
Tööstusharu
Biotehnoloogia
Riik
United Kingdom
Kauplemisstatistika
Keskmine maht
1.32M
Börs
NCM
Valuuta
USD
52 nädala vahemik
Seotud uudised
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO
Pomerantz LLP is investigating claims on behalf of investors of Mereo BioPharma Group plc ("Mereo" or the "Company") (NASDAQ: MREO). Such investors...
JP Morgan Maintains Overweight on Mereo BioPharma Group, Raises Price Target to $8
JP Morgan analyst Priyanka Grover maintains Mereo BioPharma Group with a Overweight and raises the price target from $7 to $8.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO
Pomerantz LLP is investigating claims on behalf of investors of Mereo BioPharma Group plc ("Mereo" or the "Company") (NASDAQ: MREO). Such investors...
āshibio Expands Clinical Pipeline with Vantictumab, a First-In-Class Antibody for Autosomal Dominant Osteopetrosis Type 2
- Company's second clinical-stage asset licensed from Mereo Biopharma based on novel insights generated in a mouse model of osteopetrosis - - āshibio has exclusive license to develop and commercialize vantictumab
Mereo BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Highlights
Data from Phase 3 Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta expected around year-end 2025 Cash of $56.1 million as of June 30, 2025, expected to support operations into 2027 LONDON, Aug. 12,
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO
Pomerantz LLP is investigating claims on behalf of investors of Mereo BioPharma Group plc ("Mereo" or the "Company") (NASDAQ: MREO). Such investors...
Seotud aktsiad
Püsi kursis
Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.